Tacton Launches Portfolio Performance Intelligence to Help Manufacturers Understand Why Products Win
30.6.2026 15:00:00 CEST | Business Wire | Press release
New configuration-aware commercial intelligence capability connects customer requirements, configuration decisions, and business outcomes to optimize win rates, margin and product strategy.
Tacton, a global leader in Configure, Price, Quote (CPQ) solutions for manufacturers of complex products, today announced the launch of Portfolio Performance Intelligence, a new analytics capability designed to help manufacturers understand why products win, where margin is created or lost, and which decisions consistently drive successful business outcomes.
Manufacturers don't lack data. They lack the context needed to understand why products perform the way they do and why customers choose them.
ERP systems show what was sold, CRM platforms track opportunities, and BI tools visualize trends. But when manufacturers try to understand which customer requirements drive demand, which configurations consistently win, or why margins vary across products, regions or segments, the answers are often unclear.
That's because the most important layer of insight–the connection between customer needs, configuration decisions and deal outcomes–only exists within CPQ.
“As product complexity increases and margin pressure continues to grow, manufacturers need more than just historical reporting,” said Jesper Alfreddson, Chief Product Officer at Tacton. “Portfolio Performance Intelligence extends Tacton CPQ with configuration-aware commercial intelligence, helping teams get direct visibility into how product, pricing, and configuration decisions impact business outcomes, so they can act faster and more confidently.”
Built directly into Tacton CPQ, Portfolio Performance Intelligence connects customer requirements, configuration decisions, pricing, and business outcomes to help manufacturers understand what drives revenue, margin, and portfolio performance. By revealing which configurations, features, and pricing decisions consistently lead to successful outcomes, manufacturers can replicate what works across products, regions, and customer segments.
With Portfolio Performance Intelligence, product, sales, and commercial teams can:
- Identify the configuration patterns that consistently drive wins
- Understand which products, features and combinations protect margin
- Reduce unnecessary portfolio complexity and low-performing variants
- Improve sales velocity by identifying where deals slow down or stall
- Improve future pricing, portfolio forecasting and go-to-market decisions
Unlike traditional analytics environments that require manual data preparation and recreation of complex product logic, Portfolio Performance Intelligence is purpose-built for configurable manufacturing and embedded directly within Tacton CPQ, where customer requirements become product, pricing, and configuration decisions.
As manufacturers face increasing pressure to manage complexity, improve efficiency and protect profitability, the ability to connect decisions to outcomes is critical.
Portfolio Performance Intelligence is the latest capability within Tacton Insights & Analytics, Tacton's embedded analytics platform designed to help manufacturers unlock the full value of CPQ data. The platform also includes Behavior & Engagement Analytics, providing visibility into CPQ adoption and usage.
Portfolio Performance Intelligence will be available in July 2026. Learn more here.
About Tacton
Tacton is a global leader in software for manufacturers of highly configurable products. Tacton delivers the Buyer-Centric Smart Factory, connecting buyer engagement with engineering and order fulfillment through a single source of truth.
By uniting Configure Price and Quote, Configuration Lifecycle Management, and Configured Order Fulfillment, Tacton helps manufacturers manage complexity, protect margins, and deliver with confidence across the lifecycle.
With more than 26 years of experience, Tacton supports manufacturers worldwide and is headquartered in Stockholm, Sweden and Chicago, USA. Learn more at www.tacton.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260630278615/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
90% of IT Leaders See Gaps in AI Threat Readiness, Lenovo Brings Single Point of Accountability to Cyber Resiliency30.6.2026 15:00:00 CEST | Press release
New end-to-end resilience and managed security offerings help organizations reduce security complexity, cut system downtime by up to 50%, and lower remediation costs by up to 40% by bringing devices, security technologies, expert services, and ecosystem partners together under a single operational model As organizations accelerate AI adoption and digital workplace transformation, many are finding that cyber resilience is undermined not by a lack of security tools, but by growing operational complexity and threat sophistication. According to recent research, 90% of IT leaders acknowledge gaps in their ability to defend against AI-driven threats. While security investments continue to grow, many organizations face a different challenge: fragmented accountability. Security operations remain highly distributed and siloed, making it increasingly difficult to coordinate response efforts, maintain end-to-end business continuity, and recover quickly when incidents occur. To help organizations
SC Therapeutics Initiates REACH2 Trial for Refractory Chronic Cough30.6.2026 15:00:00 CEST | Press release
First-in-class disease-modifying therapeutic aerosol targeting mechano-sensitive ion channels advances into phase 2 clinical evaluation in UK SC Therapeutics, a clinical-stage biopharmaceutical company pioneering therapies that deactivate mechano-sensitive ion channels (MSCs) to treat respiratory and cardiovascular disease, today reports initiation of the REACH2 trial. The study will evaluate the Company's lead product candidate in patients with refractory chronic cough (RCC) – a debilitating condition for which no disease-modifying treatment options currently exist. The trial will be run in three major cough centers across the UK. A Novel, Disease-Modifying Mechanism of Action SC0032, SC Therapeutics' most advanced product candidate, is a proprietary therapeutic aerosol composed entirely of ions endogenous to human airways. Unlike current symptomatic investigational drugs – including P2X3 receptor antagonists and neurokinin-1 (NK1) receptor antagonists that seek to dampen neural hyper
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom